Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection

Massive production of efficacious SARS-CoV-2 vaccines is essential for controlling the ongoing COVID-19 pandemic. We report here the preclinical development of yeast-produced receptor-binding domain (RBD)-based recombinant protein SARS-CoV-2 vaccines. We found that monomeric RBD of SARS-CoV-2 could...

Descripción completa

Detalles Bibliográficos
Autores principales: Zang, Jinkai, Zhu, Yuanfei, Zhou, Yu, Gu, Chenjian, Yi, Yufang, Wang, Shuxia, Xu, Shiqi, Hu, Gaowei, Du, Shujuan, Yin, Yannan, Wang, Yalei, Yang, Yong, Zhang, Xueyang, Wang, Haikun, Yin, Feifei, Zhang, Chao, Deng, Qiang, Xie, Youhua, Huang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372230/
https://www.ncbi.nlm.nih.gov/pubmed/34408130
http://dx.doi.org/10.1038/s41421-021-00315-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372230/
https://www.ncbi.nlm.nih.gov/pubmed/34408130
http://dx.doi.org/10.1038/s41421-021-00315-9

Ejemplares similares